DK104994A - Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus - Google Patents

Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Info

Publication number
DK104994A
DK104994A DK104994A DK104994A DK104994A DK 104994 A DK104994 A DK 104994A DK 104994 A DK104994 A DK 104994A DK 104994 A DK104994 A DK 104994A DK 104994 A DK104994 A DK 104994A
Authority
DK
Denmark
Prior art keywords
treatment
hiv
formula
hepatitis
pharmaceuticals
Prior art date
Application number
DK104994A
Other languages
Danish (da)
Inventor
Roelf Datema
Zsuzanna Maria Ilona Kovacs
Karl Nils Gunnar Johansson
Bjoern Gunnar Lindborg
Goeran Bertil Stening
Bo Fredrik Oeberg
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of DK104994A publication Critical patent/DK104994A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A compound of formula (I), wherein the radicals A, X, R<1>, R<2>, and R<3> are defined as follows: A: formula (a) or formula (b); X: (a) O; (b) S; (c) CH2; R<1>: H; alkyl containing 1-3 carbon atoms; -CH=CH2; -CH=CH-CH3; -CH2-CH=CH2; formula (II); -C=CH; R<2>: H; or R<2> constitutes together with R<3> a carbon-carbon bond; R<3>: H; F; Cl; Br; I; N3; CN; C=CH; OH; OCH3; CH2OH; and when R<3> is F; Cl; Br; I; N3; CN; C=CH; OH; OCH3 or CH2OH it may have either the cis-configuration or trans-configuration relative to the hydroxymethyl function at position 4', or R<3> constitutes together with R<2> a carbon-carbon bond, and therapeutically acceptable salts thereof, for use in therapy, in particular for the treatment of HIV virus infections.
DK104994A 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus DK104994A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8701605A SE8701605D0 (en) 1987-04-16 1987-04-16 NOVEL MEDICINAL COMPOUNDS
CA000580141A CA1336088C (en) 1987-04-16 1988-10-14 1-(3'-substitued-2', 3'-dideoxy-d-ribofuranosyl) thymine and uracil

Publications (1)

Publication Number Publication Date
DK104994A true DK104994A (en) 1994-09-13

Family

ID=25672174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK696988A DK168443B1 (en) 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds
DK911084A DK108491D0 (en) 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS
DK104994A DK104994A (en) 1987-04-16 1994-09-13 Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK696988A DK168443B1 (en) 1987-04-16 1988-12-15 Pyrimid-2-on-1-yl compounds, pharmaceutical preparations which comprise these compounds, and a process for preparing the compounds
DK911084A DK108491D0 (en) 1987-04-16 1991-06-07 NUCLEOSIDES AND NUCLEOSIDALALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE RELATIONSHIPS

Country Status (9)

Country Link
JP (1) JPH01503069A (en)
AT (1) ATE115958T1 (en)
AU (1) AU614082B2 (en)
CA (1) CA1336088C (en)
DE (1) DE3852531T2 (en)
DK (3) DK168443B1 (en)
HU (1) HU211547A9 (en)
SE (1) SE8701605D0 (en)
WO (1) WO1988008001A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4950758A (en) * 1988-01-20 1990-08-21 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
DE68917479D1 (en) * 1988-02-24 1994-09-15 Inst Rech Chim Biolog DERIVATIVES OF DEOXY-2'-URIDINE SUBSTITUTED IN THE 5, 3 'OR 5' POSITION BY ACYLATED ALPHA-AMINO GROUPS, METHOD FOR THE PRODUCTION AND MEDICINAL PRODUCTS THEREOF.
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
FI95384C (en) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Process for the preparation of 3'-deoxy-3'-substituted methyl nucleosides and intermediates used in the process
FR2648045B1 (en) * 1989-06-13 1991-09-27 Centre Nat Rech Scient ALPHA ANOMERIC OLIGONUCLEOTIDE COMPOUNDS INHIBITING REPLICATION OF RETROVIRUSES
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
DE69034209T2 (en) * 1989-09-15 2006-08-10 Southern Research Institute, Birmingham 2'-DEOXY-4'-THIORIBONUCLEOSIDE AS ANTIVIRAL AND ANTIBODY
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
SE9003151D0 (en) * 1990-10-02 1990-10-02 Medivir Ab NUCLEOSIDE DERIVATIVES
JP2960164B2 (en) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes having antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
EP0637965B1 (en) * 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
AU697612B2 (en) * 1994-05-31 1998-10-15 Medivir Ab Post exposure prevention of HIV
US5612319A (en) * 1994-05-31 1997-03-18 Medivir Ab Postexposure prevention of HIV infection or seroconversion
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP1655033A1 (en) 1995-06-07 2006-05-10 Emory University Nucleosides with anti-hepatitis B virus activity
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
DK1058686T3 (en) 1998-02-25 2007-03-05 Univ Emory 2'-fluoro nucleosides
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
SI2084175T1 (en) 2006-10-10 2011-05-31 Medivir Ab Hcv nucleoside inhibitor
JP6270742B2 (en) * 2013-01-10 2018-01-31 塩野義製薬株式会社 Method for producing cross-linked nucleic acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD75084A (en) *
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
FR2040177A1 (en) * 1969-01-31 1971-01-22 Robugen Gmbh 2-deoxyribosyl-uracil derivs
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2918260A1 (en) * 1979-05-07 1980-11-27 Robugen Gmbh 5-alkyl-5'-deoxy-uridine deriVs. use - for normalising cancerous cell functions and accelerating wound healing
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
DE2930904A1 (en) * 1979-07-30 1981-02-19 Kailash Kumar Dr Gauri Antitumour use of 5-alkyl-pyrimidine nucleoside derivs. - as potentiators of 5-fluoro-uracil
DE3002197A1 (en) * 1980-01-22 1981-07-23 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Alkyl- and 5-alkenyl-uracil and -cytidine nucleoside derivs. - prepd. e.g. by reaction of 5'-chloro-5'-deoxy cpds. with ammonia
DE3045375A1 (en) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Substd. pyrimidine nucleoside derivs. - useful as antiviral agents
DE3229169A1 (en) * 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Use of 5-alkylpyrimidine nucleosides and their derivatives as cytostatics
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CY1508A (en) * 1985-03-16 1990-08-03 Wellcome Found Antiviral nucleosides
CA1285935C (en) * 1985-03-16 1991-07-09 Janet Lister Rideout Therapeutic nucleosides
PT82580B (en) * 1985-05-15 1989-01-17 Wellcome Found Process for the preparation of 2 ', 3'-DIDESOXINUCLEOSIDOS AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
DK167377B1 (en) * 1985-09-17 1993-10-25 Wellcome Found 3'-AZIDOPYRIMIDINE NUCLEOSIDES OR PHARMACEUTICAL ACCEPTABLE SALTS OR ESTERS THEREOF USED FOR TREATMENT OR PROPHYLAXY FOR A HUMAN RETROVIRUS INFECTION

Also Published As

Publication number Publication date
CA1336088C (en) 1995-06-27
SE8701605D0 (en) 1987-04-16
DE3852531D1 (en) 1995-02-02
AU1689988A (en) 1988-11-04
DK108491A (en) 1991-06-07
DK696988A (en) 1989-01-31
WO1988008001A1 (en) 1988-10-20
DK696988D0 (en) 1988-12-15
ATE115958T1 (en) 1995-01-15
JPH01503069A (en) 1989-10-19
HU211547A9 (en) 1995-12-28
DK108491D0 (en) 1991-06-07
DE3852531T2 (en) 1995-08-10
AU614082B2 (en) 1991-08-22
DK168443B1 (en) 1994-03-28

Similar Documents

Publication Publication Date Title
DK104994A (en) Use of Beta-Anomeric Compounds for the Preparation of Pharmaceuticals for the Treatment or Prevention of HIV or Hepatitis B Virus
DK0565549T3 (en) Use of 1,3-oxathiolannucleoside analogues for the preparation of a preparation for the treatment of hepatitis B
FI894545A (en) THERAPEUTIC NUCLEOSIDER.
KR900701817A (en) Nucleoside derivatives and preparation methods thereof
IL86040A (en) Acid stable purine dideoxynu- cleosides, their preparation and pharmaceutical compositions containing them
SE8704298D0 (en) COMPOUNDS FOR USE IN THERAPY
DK0543000T3 (en) Process for preparing 3-amino-2-chloro-4-alkylpyridines
SE8605503D0 (en) NOVEL MEDICINAL USE
FI870090A (en) LAONGKEDJADE ALKYLRESORCINOLPHOSFITER.
DK0551459T3 (en) Process for preparing 3-amino-2-chloro-4-alkylpyridines
KR880007070A (en) Pharmaceutical composition for cataract treatment
ES2038600T3 (en) COMPOSITIONS FOR THERAPEUTIC USE UNDERSTANDING ORGAN-SILICON COMPOUNDS.
GR78622B (en)
BR9915993A (en) Compound, pharmaceutical composition, process to inhibit the replication of a herpes virus, and process to treat a patient suffering from a herpes virus infection
ES8308335A1 (en) Antiviral deoxyuridine compounds.
ES2105599T3 (en) COMPOSITIONS CONTAINING ANALOG COMPOUNDS WHEN ACICLOVIR AND NUCLEOSIDIC ANALOGS REPLACED BY VINYL IN POSITION 2 &#39;USED IN THE TREATMENT OF VIRAL INFECTIONS.
IT1245631B (en) Use of macrolide compounds as anti-inflammatory agents for the treatment of diseases caused by histamine release
ES2013350A6 (en) A procedure for preparing nucleosides and analogues of nucleosides
MX9202634A (en) USE OF 1,3-OXATIOLANE NUCLEOSIDE ANALOGS IN THE TREATMENT OF HEPATITIS B.
GR1000522B (en) Preparation method of new analogue nucleozites
ES2078139B1 (en) ANTIRRETROVIRAL COMPOSITIONS CONTAINING IODINE COMPOUNDS.
TH7865EX (en) Different derivatives of nucleosides
TH13993EX (en) The use of iridoid compounds for the treatment of hepatitis B (HBV) infection.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment